Epidermolysis Bullosa Care and Treatment market - Forecasts from 2021 to 2026
発行: Knowledge Sourcing Intelligence
ページ情報: 英文 109 Pages
世界の表皮水疱症 (EB) 向けケア・治療の市場規模は、2019年には14億5376万1000米ドル、2026年には21億915万米ドルに達する見通しです。また、予測期間中に5.46％のCAGRで成長すると考えられています。現時点でEB向けの治療薬は上市されておらず、通常は疼痛管理や創傷ケア、栄養サポート、感染症予防、合併症の治療・予防といったケアが取られれています。一方、世界各国で大手製薬企業により、複数のEB治療薬の開発・治験が進行中です。
The global Epidermolysis Bullosa care and treatment market is expected to grow at a compound annual growth rate of 5.46% over the forecast period to reach a market size of US2,109.150 million in 2026, from US$1,453.761 million in 2019. Epidermolysis Bullosa (EB) is known as a rare and infrequent medical condition that results in mucous membranes and easy blistering of the skin. The disease is due to the mutation of at least one in the sixteen different genes. There has not been a cure for this rare condition. Management usually involves pain control, wound care, nutritional support, controlling infections, and treatment or prevention of complications. Major companies have been developing novel and solutions for the treatment of this rare problem. Government funding and support, worldwide, have been imperative for the prevention and treatment of this rare medical condition. In December 2018, Fibrocell Science Inc, which has now been acquired by Castle Creek Pharmaceutical, had received US$900,000 from Epidermolysis Bullosa Research Foundation and EB Research Partnership to advance the company's FCX-007 gene therapy for the treatment of EB. Epidermolysis Bullosa is termed a genetic disease. There are three types of EB, known as EB simplex, Dystrophic EB, and Junctional EB.
EB has been becoming one of the major medical conditions, worldwide. Around 500,000 people are being affected by EB, globally, according to several official sources. According to the data given by the National Epidermolysis Bullosa Registry, an estimated number of twenty newborns per one million live births in the United States has Epidermolysis Bullosa. There has not been an exact number of people with EB, but several estimates and official projections showed that around 25,000-50,000 people in the United States, have Epidermolysis Bullosa. Moreover, according to several official publications, the prevalence rate had increased in the past twenty years. These trends are expected to have a positive impact on the market, as the investment in the treatment of EB Is expected to surge in the coming years. In May 2021, Elon-gate, a cryptocurrency token for charitable giving, announced that it had donated US$150,000 to the EB research partnership (EBRP), the biggest worldwide non-profit funding research to discover and provide cures and treatments for EB. The EBRP funds research and development projects that study groundbreaking technologies, such as exon skipping, gene editing, and stem cell therapies, to cure EB by the year 2030. Other companies and institutions have also been making significant developments in the market. For instance, in April 2021, Onconova Therapeutics Inc., a biopharmaceutical firm focused on discovering and developing new and advanced products for patients with cancer, announced that their first and novel patients had been dosed in the company's Phase 2 study to learn and assess the safety and efficacy of rigosertib in patients with recessive dystrophic epidermolysis bullosa, advanced squamous cell carcinoma. The patient was dosed at EB House Austria, which has been a center for EB at the University Hospital Salzburg. This development is expected to have a positive impact on the market, during the forecast period. Various studies by the major and reputed institutions, private firms, and hospitals are having a substantial impact on the market. The development of novel, innovative and advanced solutions for the cure and treatment of EB is likely to surge in the coming years. With the COVID-19 pandemic affecting the global population, there has been a serious discussion to increase the investment in the treatment of rare genetic diseases. In October 2020, it was announced that a phase 2 trial of PTR-01, which has been a treatment for recessive dystrophic epidermolysis bullosa, had been dosed in its novel patient. The study had been taking place at Children's Hospital Colorado and Stanford University. These developments are expected to have a positive impact on the market, during the forecast period.
Major companies have been making significant developments in the market. The increase in the enrollment of patients for company's and medical institutions trials are likely to have a positive impact on the EB care and treatment market. For instance, in August 2019, RegeneRx Biopharmaceuticals Inc., a drug development company focused on tissue repair, protection, and regeneration, announced that their first and novel patient enrolled in phase 2 trial of epidermolysis bullosa had reacted positively to the company's novel and advanced drug candidate called as RGN-137. The trial had been sponsored by Lenus Therapeutics LLC, a joint venture owned by Yuang DNU Co. Ltd., and GtreeBNT, to develop RGN-137 in Canada, the USA, Japan, Korea, and Europe. The company has been making significant developments in the market, in the past few years. Other players are also making a substantial impact in the EB care and treatment market. For instance, in September 2020, InMed Pharmaceuticals, a clinical-stage pharmaceutical firm, had announced that all of their patients, that had participated in their second phase-1 trial to treat EB, with INM-755, had completed treatment. The company had been developing INM-755 to treat EB and other dermatological diseases. The firm's clinical trial had been a vehicle-controlled, double-blind, and randomized phase 1 study to examine and assess the tolerability and safety of INM-755 cream, that had been applied and rubbed on epidermal wounds in healthy volunteers. This development is expected to have a positive impact on the market, during the forecast period. The rise and growth in investment and funding in the treatment of EB has made a significant impact in the market. Castle Creek Pharmaceutical has been making substantial developments in the market. The company had acquired Fibrocell Science and has become a major player in the development of treatments and cures for epidermolysis bullosa. The company has also been developing FCX-007, an investigational gene therapy, for the treatment of recessive dystrophic epidermolysis bullosa. FCX-007, the company's novel solutions, had been a cell-based therapy that is used to genetically modify the patient's dermal fibroblasts. These developments are expected to have a positive impact on the market, during the forecast period.